Serum markers of cutaneous melanoma

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 3, 2010, Pages 1115-1122

  Perrotta, Rosario ^a   Bevelacqua, Ylenia ^a   Malaguarnera, Giulia ^a   Paladina, Isabella ^a   Giordano, Maria ^a   Malaguarnera, Mariano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cutaneous melanoma; Diagnosis; Prognosis; Review; Serum biomarkers

Indexed keywords

TUMOR MARKER;

BLOOD; HUMAN; MELANOMA; REVIEW; SKIN TUMOR;

HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957361083     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Garbe, C., K. Peris, A. Hauschild, P. Saiag, M. Middleton, A. Spatz, J. J. Grob, J. Malvehy, J. Newton-Bishop, A. Stratigos, H. Pehamberger & A. Eggermont: Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. (Epub ahead of print) (2009)
2. Balzi, D., P. Carli & M. Geddes: Malignant melanoma in Europe: changes in mortality rates (1970-90) in European Community countries. Cancer Causes Control. 8(1), 85-92 (1997) (Pubitemid 27092946)
3. Harrison, S. L., R. MacLennan & P. G. Buettner: Sun exposure and the incidence of melanocytic nevi in young Australian children. Cancer Epidemiol Biomarkers Prev. 17(9), 2318-24 (2008).
4. Bulliard, J. L., R. G. Panizzon & F. Levi: Epidemiology of epithelial skin cancers. Rev Med Suisse. 5(200), 882-8. (2009)
5. Bulliard, J. L., M. Maspoli, R. G. Panizzon, D. Hohl, F. Gueissaz & F. Levi: Evaluation of the Euromelanoma skin cancer screening campaign: the Swiss experience. J Eur Acad Dermatol Venereol. 22(3), 365-6 (2008) (Pubitemid 351247431)
6. Jemal, A., S. S. Devesa, T. R. Fears & P. Hartge: Cancer surveillance series: changing patterns of cutaneous malignant melanoma mortality rates among whites in the United States. J Natl Cancer Inst. 92(10), 811-8 (2000) (Pubitemid 30368037)
7. Shin, S., B. E. Palis, J. L. Phillips, A. K. Stewart & R. R. Perry: Commission on Cancer Melanoma Disease Site Team: Cutaneous melanoma in Asian-Americans. J Surg Oncol. 99(2), 114-8 (2009)
8. Linos, E., S. M. Swetter, M. G. Cockburn, G. A. Colditz & C. A. Clarke: Increasing burden of melanoma in the United States. J Invest Dermatol. 129(7), 1666-74 (2009)
9. Malaguarnera, M., M. Vinci & G. Pistone: Malignant melanoma of nasal cavity: case report and review of the literature. Cancer Biother Radiopharm 17, 29-34 (2002) (Pubitemid 34208169)
10. Malaguarnera, M., M. Romano & G. Pistone: Metastatic melanoma of the nasal cavity in a patient with oculocutaneous albinism. Clin Oncol (R Coll Radiol) 10(6), 404-6 (1998) (Pubitemid 29015250)
11. Malaguarnera, M., G. Pistone, L. Succi, T. Pontillo, A. Laurino & D. Russello: Malignant anorectal melanoma: description of a clinical case and review of the literature. Bull Cancer 84, 423-6 (1997) (Pubitemid 27257167)
12. Garbe, C., P. Büttner, J. Bertz, G. Burg, B. d'Hoedt, H. Drepper, I. Guggenmoos-Holzmann, W. Lechner, A. Lippold, C. E. Orfanos, A. Peters, G. Rassner, R. Stadler & W. Stroebel: Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75(10), 2484-91 (1995)
13. Donato, R.: S-100 proteins. Cell Calcium 7, 123-45 (1986)
14. Kawasaki, H., S. Nakayama & R. H. Kretsinger: Classification and evolution of EF-hand proteins. Biometals 11, 277-95 (1998) (Pubitemid 29121537)
15. Zimmer, D. B., E. H. Cornwall, A. Landar & W. Song: The S100 protein family: history, function and expression. Brain Res. Bull. 37, 417-29 (1995)
16. Marenholz, C. W. Heizmann & G. Fritz: S100 proteins in mouse and man: from evolution to function and pathology (including an update of nomenclature). Biochem. Biophys Res. Commun. 322, 1111-22 (2004) (Pubitemid 39164640)
17. Böni, R., C. W. Heizmann, A. Doguoglu, E. G. Ilg, B. W. Schäfer, R. Dummer & G. Burg: Ca (2+)-binding proteins S100A6 and S100B in primary cutaneous melanoma. J. Cutan. Pathol. 24, 76 (1997)
18. Ribe, A. & N. S. McNutt: S100A6 protein expression is different in Spitz nevi and melanomas. Mod. Pathol. 16, 505 (2003)
19. Donato, R.: Perspectives in S-100 protein biology. Cell Calcium 12, 713-26 (1991)
20. Wilder, P. T., R. R. Rustandi, A. C. Drohat & D. J. Weber: S-100 (beta beta) inhibits the protein kinase Cdependent phosphorylation of a peptide derived from p53 in a Ca2+-dependent manner. Protein Sci. 7, 794-8 (1998)
21. van Eldik, L. J., R. A. Jensen, B. A. Ehrenfried & Jr W. O. Whetsell: Immunohistochemical localization of S 100 beta in human nervous system tumors by using monoclonal antibodies with specificity for the S 100 beta polypeptide. J. Histochem. Cytochem. 34, 977-82 (1986) (Pubitemid 16058090)
22. Gaynor, R., R. Irie, D. Morton & H. R. Herschman: S 100 protein is present in cultured human malignant melanoma. Nature 286, 400-1 (1980) (Pubitemid 10002887)
23. Fagnart, O. C., C. J. M. Sindic & C. Laterre: Particle counting immunoassay of S-100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin. Chem. 34, 1387-1391 (1988)
24. Jackal, A., M. Diechman, V. Waldmann, M. Bock & H. Naher: S100β protein in serum, a tumor marker in malignant melanoma-current state of knowledge and clinical experiences. Hautarzt 50, 250-6 (1999) (Pubitemid 29200322)
25. Guo, H. B., B. Stoffel-Wagner, T. Bierwirth, J. Mezger & D. Klingmuller: Clinical significance of serum S100 in metastatic melanoma. Eur. J. Cancer 31 A, 924-8 (1995)
26. Kaskel, P., C. Berking, S. Sander, M. Volkenandt, R. U. Peter & G. Kran: S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J. Am. Acad. Dermatol. 41, 962-9 (1999)
27. Abraha, H. D., L. C. Fuller, A. W. P. du Vivier. E. M. Higgins & R. A. Sherwood: Serum S100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br. J. Dermatol. 137, 381-5 (1997) (Pubitemid 27421564)
28. Molina, R., J. Navarro, X. Filella, T. Castel & A. M. Ballesta: S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 23, 39-44 (2002) (Pubitemid 34225020)
29. Acland, K., A. V. Evans, H, Abraha, C. M. J. Healy, P. Roblin, E. Calonje, G. Orchard, E. Higgins, R. Sherwood & R. Russel-Jones: Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. British Journal of Dermatology 146, 832-835 (2002) (Pubitemid 34539193)
30. Djureen-Martensson, E., L. O. Hasson, B. Nilsson, E. von Schoultz, E. Mansson Brahme, U. Ringborg & J. Hansson: Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 19, 824-31 (2001) (Pubitemid 32119098)
31. von Schoultz, E., L. O. Hansson, E. Djureen, J. Hansson, R. Karnell, B. Nilsson, T. Stigbrand & U. Ringborg et al.: Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 30, 295-7 (1996)
32. Karnell, R., E. von Schoultz, L. O. Hansson, B. Nilsson, K. Arstrand & B. Kagedal: S 100B protein, 5-Scysteinyldopa and 6-hydroxy-5- methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 7, 393-9 (1997) (Pubitemid 27508730)
33. Wibe, E., E. Paus & S. Aamdal: Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Lett. 52, 29-31 (1990) (Pubitemid 20185573)
34. Wibe, E., E. Hannisdal, E. Paus & S. Aamdal: Neuronspecific enolase as a prognostic factor in metastatic malignant melanoma. Eur. J. Cancer 28 A, 1692-1695 (1992)
35. Butler, W. T.: The nature and significance of Osteopontin. Connect Tissue Res 23, 123-136, (1989)
36. Denhardt, D., & X. Guo: Osteopontin: a protein with diverse functions. FASEB J 7, 1475-1482 (1993) (Pubitemid 24003267)
37. Prince, C. W.: Secondary structure predictions for rat Osteopontin. Connect Tissue Res 21, 15-20 (1989)
38. Weber, G. F., S. Akshar, M. J. Glimcher & H. Cantor: Receptorligand interaction between CD44 and osteopontin (Eta-1). Science 271, 509-519 (1996)
39. Rittling, S. R. & A. F. Chambers: Role of osteopontina in tumour progression. BJ Cancer 90(10), 1877-81 (2004)
40. Raganswami, H., A. Bubule & G. C. Kundu: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16, 79-87 (2006) (Pubitemid 43247403)
41. Furger, K. A., R. K. Menon, A. B. Tuck, V. H. Bramwell & A. F. Chambers: The functional and the clinical roles of osteopontina in cancer and metastasis. Curr Mol Med. 1(5), 621-32 (2001) (Pubitemid 33772040)
42. El-Tanani, M. K.: Role of osteopontin in cellular signaling and methastatic phenotype. Front Biosci. 13, 4276-84 (2008) (Pubitemid 351599683)
43. Fedarko, N. S., A. Jain, A. Karadag, M. R. Van Eman & L. W. Fisher: Elevated serum bone sialoprotein and osteopontina in colon, breast prostate and lung cancer. Clin Cancer Res. 7(12), 4060-6 (2001) (Pubitemid 34044628)
44. El-Tanani, M. K., F. C. Campbell, V. Kurisetty, D. Jin, M. Mc Cann & P. S. Rudland: The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growt Factor Rev. 17(6), 463-74 (2006) (Pubitemid 44793123)
45. Rangel, J., M. Nosrati, S. Torabian, L. Shaikh, S. P. Leong & M. Kashani-Sabet: Osteopontin as a molecular prognostic marker for melanoma. Cancer 12(1), 144-50 (2008)
46. Coppola, D., M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A. F. Chambers & T. J. Yeatman: Correlation of osteopontina protein expression and pathological stage across awide variety of tumor histologies. Clin Cancer Res. 10, 184-90 (2004) (Pubitemid 38114178)
47. Denhardt, D. T., D. Mistretta, A. F. Chambers, S. Krishna, J. F. Porter, S. Raghuram & S. R. Rittling: Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 20, 77-84 (2003) (Pubitemid 36308139)
48. Denhardt, D. T., C. M. Giachelli & S. R. Rittling: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 41, 723-49 (2001) Review. (Pubitemid 32385904)
49. Wang-Rodriguez, J., V. Urquidi, A. Rivard & S. Goodison: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 5(5), 136-43 (2003)
50. Castellano, G., G. Malaponte, M. C. Mazzarino, M. Figini, F. Marchese, P. Gangemi, S. Travali, F. Stivala, S. Canevari & M. Libra: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 14(22), 7470-80 (2008)
51. Carlinfante, G., D. Vassiliou, O. Svensson, M. Wendel, D. Heinegård & G. Andersson: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20(5), 437-44 (2003) (Pubitemid 37108430)
52. Yeatman, T. J. & A. F. Chambers: Osteopontin and colon cancer progression. Clin Exp Metastasis. 20(1), 85-90 (2003) Review (Pubitemid 36308140)
53. Le, Q. T., P. D. Sutphin, S. Raychaudhuri, S. C. Yu, D. J. Terris, H. S. Lin, B. Lum, H. A. Pinto, A. C. Koong & A. J. Giaccia: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 9(1), 59-67 (2003) (Pubitemid 36109716)
54. Gotoh, M., M. Sakamoto, K. Kanetaka, M. Chuuma & S. Hirohashi: Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 52(1), 19-24 (2002) (Pubitemid 34299209)
55. Rangel, J., M. Nosrati, S. Torabian, L. Shaikh, S. P. Leong, C. Haqq, J. R. Miller 3rd, R. W. Sagebiel & M. Kashani-Sabet: Osteopontin as a molecular prognostic marker for melanoma. Cancer. 112(1), 144-50 (2008)
56. Blesch, A., A. K. Bosserhoff, R. Apfel, C. Behl, B. Hessdoerfer, A. Schmitt, P. Jachimczak, F. Lottspeich, R. Buettner & U. Bogdahn: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 54(21), 5695-701 (1994) (Pubitemid 24346269)
57. van Groningen, J. J., H. P. Bloemers & G. W. Swart: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res. 55(24), 6237-43 (1995)
58. Hau, P., P. Wise, A. K. Bosserhoff, A. Blesch, P. Jachimczak, I. Tschertner, U. Bogdahn & R. Apfel: Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanomaderived growth-inhibiting activity (MIA/CD-RAP). J Invest Dermatol. 119(3), 562-9 (2002)
59. Bosserhoff, A. K. & R. Buettner: Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol. 17(1), 289-300 (2002) (Pubitemid 34116431)
60. Bosserhoff, A. K.: Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res. 18(6), 411-6 (2005)
61. Bosserhoff, A. K., M. Lederer, M. Kaufmann, R. Hein, W. Stolz, R. Apfel, U. Bogdahn & R. Buettner: MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res. 19(4A), 2691-3 (1999) (Pubitemid 29392439)
62. Hau, P., P. Ruemmele, L. A. Kunz-Schughart, A. Doerfelt, B. Hirschmann, A. Lohmeier, H. Koch, A. Mueller, U. Bogdahn & A. K. Bosserhoff: Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma. Oncol Rep. 12(6), 1355-64 (2004)
63. El Fitori, J., J. Kleeff, N. A. Giese, A. Guweidhi, A. K. Bosserhoff, M. W. Büchler & H. Friess: Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell Int. 5(1), 3 (2005)
64. Mühlbauer, M., N. Langenbach, W. Stolz, R. Hein, M. Landthaler, R. Buettner & A. K. Bosserhoff: Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res. 5(5), 1099-105 (1999) (Pubitemid 29233225)
65. Bosserhoff A. K., M. Moser, R. Hein, M. Landthaler & R. Buettner: In situ expression patterns of melanomainhibiting activity (MIA) in melanomas and breast cancers. J Pathol. 187(4), 446-54 (1999) (Pubitemid 29118277)
66. Bosserhoff A. K., R. Stoll, J. P. Sleeman, F. Bataille, R. Buettner & T. A. Holak: Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest. 83(11), 1583-94 (2003) (Pubitemid 37421099)
67. Bosserhoff, A. K., B. Echtenacher, R. Hein & R. Buettner: Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 11(4), 417-21 (2001) (Pubitemid 32735233)
68. Schmidt, J. & A. K. Bosserhoff: Processing of MIA protein during melanoma cell migration. Int J Cancer (2009)
69. Koukourakis, M. I., A. Giatromanolaki & E. Sivridis: Tumour and Angiogenesis Research Group Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol. 24, 199-202 (2003) (Pubitemid 37500569)
70. Fantin, V. R., J. St-Pierre & P. Leder: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-34 (2006) (Pubitemid 43832190)
71. Sirott, M. N., D. F. Bajorin, G. Y. Wong, Y. Tao, P. B. Chapman, M. A. Templeton & A. N. Houghton: Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 15, 3091-8 (1993) (Pubitemid 23335058)
72. Eton, O., S. S. Legha, T. E. Moon, A. C. Buzaid, N. E. Papadopoulos, C. Plager, A. M. Burgess, A. Y. Bedikian, S. Ring, Q. Dong, A. B. Glassman, C. M. Balch & R. S. Benjamin: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 16, 1103-11 (1998) (Pubitemid 28108747)
73. Deichmann, M., A. Benner, M. Bock, A. Jäckel, K. Uhl, V. Waldmann & H. Näher: S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 17, 1891-6 (1999) (Pubitemid 29269262)
74. Meral, R., D. Duranyildiz, F. Tas, H. Camlica, V. Yasasever, S. Kurul & N. Dalay: Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 11, 627-32 (2001) (Pubitemid 33152354)
75. Campora, E., L. Repetto, P. Giuntini, G. Bertelli, D. Amoroso, M. R. Sertoli & R. Rosso: LDH in the follow-up of stage I malignant melanoma. Eur J Cancer Clin Oncol. 24, 277-8 (1988) (Pubitemid 18051199)
76. Walenta, S., T. Schroeder & W. Mueller-Klieser: Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem. 11, 2195-204 (2004) (Pubitemid 38967739)
77. Weissman, B. & K. Meyer: The structure of hyalobiuronic acid and of hyaluronic acid from umbilical cord. J. Am. Chem. Soc. 76, 1753-1757 (1954)
78. Itano, N., F. Atsumi, T. Sawai, Y. Yamada, O. Miyanishi, T. Senga, M. Hamaguchi & K. Kimata: Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc. Natl. Acad. Sci. 99, 3609-3614 (2002) (Pubitemid 34252154)
79. Itano, N., T. Sawai, O. Miyaishi & K. Kimata: Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 59, 2499-2504 (1999) (Pubitemid 29242303)
80. Kayser, K., G. Bohm, S. Blum, M. Beyer, S. Zink, S. Andre & H. J. Gabius: Glyco-and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J. Pathol. 193, 175-180 (2001) (Pubitemid 32118128)
81. Thylen, A., J. Wallin & G. Martensson: Hyaluronan in serum as an indicator of progressive disease in hyaluronanproducing malignant mesothelioma. Cancer 86, 2000-5 (1999)
82. Dahl, I. M., I. Turesson, E. Holmberg & K. Lilja: Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 93, 4144-8 (1999) (Pubitemid 29279256)
83. Hasselbalch, H., D. Hovgaard, N. Nissen & P. Junker: Serum hyaluronan is increased in malignant lymphoma. Am. J. Hematol. 50, 231-3 (1995) (Pubitemid 26008874)
84. Delpech, B., B. Chevallier, N. Reinhardt, J. P. Julien, C. Duval, C. Maingonnat, P. Bastit & B. Asselain: Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int. J. Cancer 46, 388-90 (1990) (Pubitemid 20291090)
85. Burchardt, E. R., R. Hein & A. K. Bosserhoff: Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clinical and Experimental dermatology 28, 515-520 (2003) (Pubitemid 37100556)
86. Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill & B. Seed: CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313 (1990)
87. Stamenkovic, I., A. Aruffo, M. Amiot & B. Seed: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 10, 343-348 (1991) (Pubitemid 21905484)
88. Miyake, K., C. B. Underhill, J. Lesleyand & P. W. Kincade: Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J. Exp. Med. 172, 69-75 (1990) (Pubitemid 20217247)
89. Culty, M., K. Miyake, P. W. Kincade, E. Silorski, E. C. Butcher & C. Underhill: The hyaluronate receptor is a member of the CD44 (HCAM) family of cell surface glycoproteins. J. Cell Biol. 111, 2765-2774 (1990) (Pubitemid 120014557)
90. Bartolazzi, A., R. Peach, A. Aruffo & I. Stamenkovic: Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 180, 53-66 (1994) (Pubitemid 24181055)
91. Colognato, H. & P. D. Yurchenco: Form and function: the laminin family of heterotrimers. Dev Dyn 218, 213-234 (2000) (Pubitemid 30349637)
92. Aumailley, M. & T. J. Krieg: Laminins: a family of diverse multifunctional molecules of basement membranes. Invest Dermatol. 106(2), 209-214 (1996) Review (Pubitemid 26094608)
93. Mortarini, R., A. Gismondi, A. Maggioni, A. Santoni, M. Herlyn & A. Anichini: Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res. 55(20), 4702-10 (1995)
94. Chen, H. B., L. Chen, J. K. Zhung, V. W. Chow, B. Q. Wu, Z. H. Wang, S. B. Cheng & E. C. Chew: Expression of laminin in metastatic melanoma cell lines with different metastatic potential. Anticancer Res. 21(1A), 505-8 (2001) (Pubitemid 32267691)
95. Riedl, S., H. Bodenmüller, U. Hinz, R. Holle, P. Möller, P. Schlag, C. Herfarth & A. Faissner: Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer 20, 64, 65-9 (1995)
96. Jones, F. S. & P. L. Jones: The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dynamics 218, 235-259 (2000) (Pubitemid 30349638)
97. Erickson, H. P. & M. A. Bourdon: Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumours. Ann. Rev. Cell Biol. 5, 71-92. (1989) (Pubitemid 19286679)
98. Shrestha, P., T. X. Austin & M. Mori: Tenascin: an extracellular matrix protein in cell growth, adhesion and cancer. Landes Bioscience (1997)
99. Orend, G.: Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 37, 1066-83 (2005) (Pubitemid 40311747)
100. Bouterfa, H., A. R. Darlapp, E. Klein, T. Pietsch, K. Roosen & J. C. Tonn: Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol. 44, 23-33 (1999) (Pubitemid 29515646)
101. Tuominen, H. & M. Kallioinen: Increased tenascin expression in melanocytic tumours. J. Cutan. Pathol. 31, 424-429 (1994) (Pubitemid 24354618)
102. Herlyn, M., U. Graeven, D. Speicher, B. A. Sela, J. L. Bennicelli, R. Kath & DuPont Guerry: Characterization of tenascin secreted by human melanoma cells. Cancer Res. 51, 4853-4858 (1991)
103. van der Rest, M. & R. Garrone: Collagen family of proteins. FASEB J 5, 2814-23 (1991) (Pubitemid 21892853)
104. Schuppan, D., T. Ruehlmann & E. G. Hahn: Radioimmunoassay for human type VI collagen and its application to tissue and body fluids. Anal. Biochem. 149, 238-247 (1985) (Pubitemid 16256974)
105. Rühl, M., E. Sahin, M. Johannsen, R. Somasundaram, D. Manski, E. O. Riecken & D. Schuppan: Soluble collagen VI drives serumstarved fibroblasts through S phase and prevents apoptosis via down-regulation of BAX. J. Biol. Chem. 274, 34361-34368 (1999) (Pubitemid 129511779)
106. Burchardt, E. R., R. Hein & A. K. Bosserhoff: Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clinical and Experimental dermatology 28, 515-520 (2003) (Pubitemid 37100556)
107. Iyengar, P., V. Espina, T. W. Williams, Y. Lin, D. Berry, L. A. Jelicks, H. Lee, K. Temple, R. Graves, J. Pollard, N. Chopra, R. G. Russell, R. Sasisekharan, B. J. Trock, M. Lippman, V. S. Calvert, E. F. Petricoin, L. Liotta, E. Dadachova, R. G. Pestell, M. P. Lisanti, P. Bonaldo & P. E. Scherer: Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 115, 1163-1176 (2005) (Pubitemid 40629035)
108. Daniels, K. J., H. C. Boldt, J. A. Martin, L. M. Gardner, M. Meyer & R. Folberg: Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab. Invest. 75, 55-66 (1996) (Pubitemid 26250273)
109. Leitinger, B. & E. Hohenester: Mammalian collagen receptors. Matrix Biol. 26, 146-155 (2007) (Pubitemid 46401227)
110. Carvalho, H. F., S. L. Felisbino, D. R. Keene & K. G. Vogel: Identification, content, and distribution of type VI collagen in bovine tendons. Cell Tissue Res. 325, 315-324 (2006) (Pubitemid 44050797)
111. Vuoristo, M., P. Vihinen, T. Vlaykova, C. Nylund, J. Heino & S. Pyrhönen: Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res. 17, 215-223 (2007) (Pubitemid 47067079)